智通财经APP获悉，美银证券发布研究报告称，将 翰森制药 (03692.HK)目标价由16.4港元调高26.8%至20.8港元，同时将投资评级从“跑输大市”上调至“买入”。
美银证券：上调翰森制药(03692.HK)评级至“买入” 目标价调高至20.8港元
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.